Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Department of General Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Pathol Res Pract. 2019 Dec;215(12):152691. doi: 10.1016/j.prp.2019.152691. Epub 2019 Oct 17.
Despite significant advances over the past decades of research, pancreatic cancer (PC) continues to have the worst 5-year survival of any malignancy. Dendritic cells (DCs) are the most potent professional antigen-presenting cells and are involved in the induction and regulation of antitumor immune responses. DC-based immunotherapy has been used in clinical trials for PC. Although safety, efficacy, and immune activation were reported in patients with PC, DC vaccines have not yet fulfilled their promise. Additional strategies for combinatorial approaches aimed to augment and sustain the antitumor specific immune response elicited by DC vaccines are currently being investigated. Here, we will discuss DC vaccination immunotherapies that are currently under preclinical and clinical investigation and potential combination approaches for treating and improving the survival of PC patients.
尽管过去几十年的研究取得了重大进展，但胰腺癌（PC）的 5 年生存率仍然是所有恶性肿瘤中最差的。树突状细胞（DC）是最有效的专业抗原呈递细胞，参与诱导和调节抗肿瘤免疫反应。基于树突状细胞的免疫疗法已在 PC 的临床试验中使用。尽管在 PC 患者中报告了安全性、疗效和免疫激活，但树突状细胞疫苗尚未实现其承诺。目前正在研究用于增强和维持树突状细胞疫苗引起的抗肿瘤特异性免疫反应的组合方法的其他策略。在这里，我们将讨论正在进行临床前和临床研究的树突状细胞疫苗免疫疗法以及治疗和改善 PC 患者生存的潜在联合方法。
